Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTH Effects on Myelination in MS
NCT02446886Phase 4Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2016
- Primary completion
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of repository corticotropin injection in multiple sclerosis (MS) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoint: Change in Myelin Water Fraction Within New Enhancing Lesions at 12 months. Started Jun 2016; status: terminated.
02
Drugs
repository corticotropin injection
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02446886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02446886.